{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:10:41Z","timestamp":1791925841942,"version":"4.3.4"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022822","name":"Merck Animal Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have transformed oncology in human medicine, providing clinical benefit in a broad spectrum of cancers. Widely available ICIs for dogs are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>Evaluate efficacy and safety of gilvetmab, a caninized anti-PD-1 monoclonal antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Fifty-one client-owned dogs were evaluated, 25 with stages II-III melanoma and 26 with stages I-III mast cell tumor (MCT). Fifteen dogs with stages III-V lymphoma were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multi-institutional, open-label study. Enrolled dogs were treated with gilvetmab IV at 6\u00a0mg\/kg q28d or 10\u00a0mg\/kg q14d; 8 dogs receiving the lower dosage underwent dose escalation with their owners\u2019 consent. Safety was evaluated by physical examinations, laboratory testing, and clinical observations made by veterinarians or the dogs\u2019 owners. Efficacy was assessed by objective response rate (ORR) and time to progression (TTP) using cRECIST v1.0 and lymphoma response criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For melanoma, the ORR was 20% (95% confidence interval [CI], 7%-41%) and median TTP was 56\u00a0days. For MCT, the ORR was 46% (95% CI, 27%-67%) and median TTP was not reached. No objective responses were observed in dogs with lymphoma. Serious adverse events of anaphylaxis, hypotension, or tumor hemorrhage occurred in 3 dogs (3\/51, 5.9%). Tumor enlargement before regression, consistent with possible pseudoprogression, was observed in 2 dogs with melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>Gilvetmab has a reasonable expectation of efficacy and an acceptable preliminary safety profile in dogs with MCT stages I-III and melanoma stages II and III.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jvimsj\/aalag098","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:02:33Z","timestamp":1780686153000},"source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor"],"prefix":"10.1093","volume":"40","author":[{"given":"Esther","family":"Chon","sequence":"first","affiliation":[{"name":"Merck Animal Health , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Morsey","sequence":"additional","affiliation":[{"name":"Merck Animal Health , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Katz","sequence":"additional","affiliation":[{"name":"Merck Animal Health , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Merck Animal Health , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Bailey","sequence":"additional","affiliation":[{"name":"Oradell Animal Hospital , Paramus, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Bergman","sequence":"additional","affiliation":[{"name":"VCA Katonah Bedford Veterinary Center , Bedford Hills, NY ,","place":["United States"]},{"name":"VCA Clinical Studies , Los Angeles, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Burr","sequence":"additional","affiliation":[{"name":"Las Vegas Veterinary Specialty Center , Las Vegas, NV ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A","family":"Clifford","sequence":"additional","affiliation":[{"name":"BluePearl Pet Hospital Malvern , Malvern, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Heeb","sequence":"additional","affiliation":[{"name":"BluePearl Veterinary Specialty Hospital in Overland Park , Overland Park, KS ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Manley","sequence":"additional","affiliation":[{"name":"The Oncology Service at the LifeCentre , Leesburg, VA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Phillips","sequence":"additional","affiliation":[{"name":"Veterinary Specialty Hospital - Sorrento Valley , San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Post","sequence":"additional","affiliation":[{"name":"MedVet Norwalk , Norwalk, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Vail","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, School of Veterinary Medicine , Madison, WI ,","place":["United States"]},{"name":"Carbone Comprehensive Cancer Center, University of Wisconsin-Madison , Madison, WI ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rusk","sequence":"additional","affiliation":[{"name":"ACI Biosciences, LLC , Chevy Chase, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L","family":"Stock","sequence":"additional","affiliation":[{"name":"Merck Animal Health , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2026060515022575900_ref1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J Clin Med"},{"key":"2026060515022575900_ref2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"2026060515022575900_ref3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026060515022575900_ref4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2026060515022575900_ref5","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"2026060515022575900_ref6","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"2026060515022575900_ref7","doi-asserted-by":"publisher","first-page":"e70324","DOI":"10.1002\/cam4.70324","article-title":"Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: a systematic review and meta-analysis","volume":"13","author":"Xu","year":"2024","journal-title":"Cancer Med"},{"key":"2026060515022575900_ref8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"2026060515022575900_ref9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"2026060515022575900_ref10","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J Cancer"},{"key":"2026060515022575900_ref11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"2026060515022575900_ref12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"2026060515022575900_ref13","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"2026060515022575900_ref14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.7150\/jca.49325","article-title":"Comparative efficacy and safety of PD-1\/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis","volume":"12","author":"Huang","year":"2021","journal-title":"J Cancer"},{"key":"2026060515022575900_ref15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026060515022575900_ref16","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"2026060515022575900_ref17","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"2026060515022575900_ref18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40364-024-00556-2","article-title":"BTLA biology in cancer: from bench discoveries to clinical potentials","volume":"12","author":"Andrzejczak","year":"2024","journal-title":"Biomark Res"},{"key":"2026060515022575900_ref19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"2026060515022575900_ref20","doi-asserted-by":"publisher","first-page":"e0235518","DOI":"10.1371\/journal.pone.0235518","article-title":"Development of canine PD-1\/PD-L1 specific monoclonal antibodies and amplification of canine T cell function","volume":"15","author":"Choi","year":"2020","journal-title":"PLoS One"},{"key":"2026060515022575900_ref21","doi-asserted-by":"publisher","first-page":"18311","DOI":"10.1038\/s41598-020-75533-4","article-title":"A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs","volume":"10","author":"Igase","year":"2020","journal-title":"Sci Rep"},{"key":"2026060515022575900_ref22","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1038\/s41598-017-09444-2","article-title":"A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma","volume":"7","author":"Maekawa","year":"2017","journal-title":"Sci Rep"},{"key":"2026060515022575900_ref23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cancers14246188","article-title":"Development of monoclonal antibodies targeting canine PD-L1 and PD-1 and their clinical relevance in canine apocrine gland anal sac adenocarcinoma","volume":"14","author":"Minoli","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026060515022575900_ref24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.vetimm.2018.02.007","article-title":"Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1","volume":"198","author":"Nemoto","year":"2018","journal-title":"Vet Immunol Immunopathol"},{"key":"2026060515022575900_ref25","doi-asserted-by":"publisher","first-page":"1144869","DOI":"10.3389\/fvets.2023.1144869","article-title":"Reversing stage III oral adenocarcinoma in a dog treated with anti-canine PD-1 therapeutic antibody: a case report","volume":"10","author":"Xu","year":"2023","journal-title":"Front Vet Sci"},{"key":"2026060515022575900_ref26","doi-asserted-by":"publisher","first-page":"2287250","DOI":"10.1080\/19420862.2023.2287250","article-title":"Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors","volume":"15","author":"Yoshimoto","year":"2023","journal-title":"MAbs"},{"key":"2026060515022575900_ref27","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1111\/jvim.16220","article-title":"2021 ACVIM Forum Research Abstract Program","volume":"35","author":"2021 ACVIM Forum Research Abstract Program","year":"2021","journal-title":"J Vet Intern Med"},{"key":"2026060515022575900_ref28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jitc-2022-005684","article-title":"Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma","volume":"10","author":"Khushalani","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026060515022575900_ref29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026060515022575900_ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512383","article-title":"Efficacy of pembrolizumab in advanced melanoma: a narrative review","volume":"24","author":"Rizzetto","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026060515022575900_ref31","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2026060515022575900_ref32","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"2026060515022575900_ref33","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"2026060515022575900_ref34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/vco.13039","article-title":"PD-L1, PD-1, and CTLA-4 mRNA In situ expression by canine oral melanoma cells and immune cells of the tumour microenvironment","volume":"23","author":"Foiani","year":"2025","journal-title":"Vet Comp Oncol"},{"key":"2026060515022575900_ref35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910387","article-title":"The comparative oncology of canine malignant melanoma in targeted therapy: a systematic review of In vitro experiments and animal model reports","volume":"25","author":"He","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026060515022575900_ref36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020394","article-title":"Naturally occurring canine melanoma as a predictive comparative oncology model for human mucosal and other triple wild-type melanomas","volume":"19","author":"Hernandez","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026060515022575900_ref37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41698-021-00147-6","article-title":"PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma","volume":"5","author":"Maekawa","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2026060515022575900_ref38","doi-asserted-by":"publisher","first-page":"e0157176","DOI":"10.1371\/journal.pone.0157176","article-title":"Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma","volume":"11","author":"Maekawa","year":"2016","journal-title":"PLoS One"},{"key":"2026060515022575900_ref39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/genes10070501","article-title":"Canine melanomas as models for human melanomas: clinical, histological, and genetic comparison","volume":"10","author":"Prouteau","year":"2019","journal-title":"Genes (Basel)"},{"key":"2026060515022575900_ref40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cells11040618","article-title":"Diagnosis, prognosis and treatment of canine cutaneous and subcutaneous mast cell tumors","volume":"11","author":"Nardi","year":"2022","journal-title":"Cells"},{"key":"2026060515022575900_ref41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.vetimm.2014.02.016","article-title":"Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications","volume":"159","author":"Ito","year":"2014","journal-title":"Vet Immunol Immunopathol"},{"key":"2026060515022575900_ref42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/01652176.2016.1152633","article-title":"Canine lymphoma: a review","volume":"36","author":"Zandvliet","year":"2016","journal-title":"Vet Q"},{"key":"2026060515022575900_ref43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/vco.283","article-title":"Veterinary cooperative oncology group\u2014common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"2026060515022575900_ref44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1476-5829.2010.00244.x","article-title":"Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer","volume":"9","author":"Lynch","year":"2011","journal-title":"Vet Comp Oncol"},{"key":"2026060515022575900_ref45","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document","volume":"13","author":"Nguyen","year":"2015","journal-title":"Vet Comp Oncol"},{"key":"2026060515022575900_ref46","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2014a veterinary cooperative oncology group (VCOG) consensus document","volume":"8","author":"Vail","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"2026060515022575900_ref47","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2026060515022575900_ref48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026060515022575900_ref49","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026060515022575900_ref50","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026060515022575900_ref51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2026060515022575900_ref52","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in Tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2026060515022575900_ref53","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2026060515022575900_ref54","volume-title":"Gilvetmab [package insert]","year":"2024"},{"key":"2026060515022575900_ref55","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s00262-023-03441-3","article-title":"The landscape of objective response rate of anti-PD-1\/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating","volume":"72","author":"Mao","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2026060515022575900_ref56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2021.09.013","article-title":"Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: a review","volume":"158","author":"Larroquette","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026060515022575900_ref57","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026060515022575900_ref58","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/j.cllc.2023.08.017","article-title":"Impact of neoadjuvant immune checkpoint inhibitors on surgery and perioperative complications in patients with non-small-cell lung cancer: a systematic review","volume":"24","author":"Takada","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2026060515022575900_ref59","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00262-021-02974-9","article-title":"ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC","volume":"71","author":"Mao","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2026060515022575900_ref60","doi-asserted-by":"publisher","first-page":"611012","DOI":"10.3389\/fonc.2021.611012","article-title":"Comparative efficacy and safety of immunotherapy alone and in combination with chemotherapy for advanced non-small cell lung cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"2026060515022575900_ref61","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/JS9.0000000000002056","article-title":"The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysis","volume":"111","author":"Yu","year":"2024","journal-title":"Int J Surg"},{"key":"2026060515022575900_ref62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers15102858","article-title":"Immune checkpoint inhibitors combined with targeted therapy: the recent advances and future potentials","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026060515022575900_ref63","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.7150\/jca.49174","article-title":"Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: a systematic review","volume":"12","author":"Ma","year":"2021","journal-title":"J Cancer"},{"key":"2026060515022575900_ref64","doi-asserted-by":"publisher","first-page":"102847","DOI":"10.1016\/j.ctrv.2024.102847","article-title":"Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: a systematic review and meta-analysis","volume":"131","author":"Villacampa","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2026060515022575900_ref65","volume-title":"AVMA News","author":"New listings in AVMA Veterinary Clinical Trials Registry","year":"2024"},{"key":"2026060515022575900_ref66","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers15113013","article-title":"Enhanced systemic antitumour immunity by hypofractionated radiotherapy and anti-PD-L1 therapy in dogs with pulmonary metastatic oral malignant melanoma","volume":"15","author":"Deguchi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026060515022575900_ref67","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamaoncol.2024.3456","article-title":"Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis","volume":"10","author":"Villacampa","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026060515022575900_ref68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1148\/radiol.2020200443","article-title":"Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis","volume":"297","author":"Park","year":"2020","journal-title":"Radiology"},{"key":"2026060515022575900_ref69","first-page":"1546","article-title":"How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy","volume":"9","author":"Ma","year":"2019","journal-title":"Am J Cancer Res"},{"key":"2026060515022575900_ref70","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026060515022575900_ref71","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Hodi","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026060515022575900_ref72","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026060515022575900_ref73","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026060515022575900_ref74","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/vco.12829","article-title":"Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: a follow-up case report","volume":"20","author":"Igase","year":"2022","journal-title":"Vet Comp Oncol"},{"key":"2026060515022575900_ref75","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.anai.2020.04.005","article-title":"Drug hypersensitivity in the fast lane: what clinicians should know about phenotypes, endotypes, and biomarkers","volume":"124","author":"Jakubovic","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026060515022575900_ref76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials","volume":"119","author":"El Osta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026060515022575900_ref77","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1200\/JCO.2015.61.0030","article-title":"Safety of infusing ipilimumab over 30 minutes","volume":"33","author":"Momtaz","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026060515022575900_ref78","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.iac.2021.12.006","article-title":"Hypersensitivity reactions and immune-related adverse events to immune checkpoint inhibitors: approaches, mechanisms, and models","volume":"42","author":"Park","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"2026060515022575900_ref79","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026060515022575900_ref80","doi-asserted-by":"publisher","first-page":"e33765","DOI":"10.1016\/j.heliyon.2024.e33765","article-title":"Characterizing immune checkpoint inhibitor-related cutaneous adverse reactions: a comprehensive analysis of FDA adverse event reporting system (FAERS) database","volume":"10","author":"Esen","year":"2024","journal-title":"Heliyon"},{"key":"2026060515022575900_ref81","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jitc-2021-003551","article-title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition","volume":"10","author":"Henderson Berg","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026060515022575900_ref82","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"2026060515022575900_ref83","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11912-018-0671-4","article-title":"Incidence and management of immune-related adverse events in patients undergoing treatment with immune checkpoint inhibitors","volume":"20","author":"Kottschade","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"2026060515022575900_ref84","doi-asserted-by":"publisher","first-page":"804597","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol"},{"key":"2026060515022575900_ref85","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2026060515022575900_ref86","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"2026060515022575900_ref87","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.4142\/jvs.23144","article-title":"Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors","volume":"25","author":"Igase","year":"2024","journal-title":"J Vet Sci"},{"key":"2026060515022575900_ref88","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.21037\/atm-20-6833","article-title":"Immune checkpoint inhibitors in lymphoma: challenges and opportunities","volume":"9","author":"Hatic","year":"2021","journal-title":"Ann Transl Med"},{"key":"2026060515022575900_ref89","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the Multicohort Single-Arm Phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026060515022575900_ref90","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/vetsci3020011","article-title":"The comparative diagnostic features of canine and human lymphoma","volume":"3","author":"Seelig","year":"2016","journal-title":"Vet Sci"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/3\/aalag098\/68482358\/aalag098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/3\/aalag098\/68482358\/aalag098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:02:35Z","timestamp":1780686155000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalag098\/8703156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalag098","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"aalag098"}}